Scholarlink

Background <p>Antimicrobial resistance (AMR) in <i>Enterococcus faecium</i>,<i> Staphylococcus aureus</i>,<i> Klebsiella pneumoniae</i>,<i> Acinetobacter baumannii</i>,<i> Pseudomonas aeruginosa</i>, and <i>Enterobacter</i> spp. (ESKAPE pathogens), notably in carbapenem-resistant <i>Acinetobacter baumannii</i>, is a pressing global health concern, contributing to significant AMR-associated mortality. Efflux pump overexpression plays a crucial role in the multidrug resistance (MDR) of <i>A. baumannii</i>, but the identification of efflux-overexpressing strains remains challenging.</p> Methods and results <p>We evaluated the performance of an efflux pump inhibition assay in comparison with RT-qPCR, to assess efflux pump overexpression in a collection of clinical <i>A. baumannii</i> strains. Sixty MDR strains and a wild one were analyzed. The inhibition assay was positive for 34 and negative for 27 strains, respectively. Results were in agreement with RT-qPCR in 67.2% of the tested strains (39/58). Cohen’s kappa showed a fair agreement between inhibition assay and RT-qPCR (Cohen’s kappa = 0.37). Inhibition by 1-(1-NaphthylMethyl)-Piperazine (NMP), but not by Phenylalanine-Arginine-β-Naphthylamide (PaβN), was in moderate agreement with RT-qPCR (Cohen’s kappa = 0.41). Furthermore, <i>gpi</i> alleles were associated with efflux pump overexpression (<i>p</i> = 0.03), suggesting potential links between genetic diversity and efflux pump overexpression. RT-qPCR showed a significant efflux pump overexpression for 4 (16.7%) out of 24 inhibition assay negative strains.</p> Conclusions <p>Our findings support the ability to reliably rule out efflux pump overexpression in <i>A. baumannii</i> strains displaying a negative result with an inhibition test relying on NMP. However, confirmatory analyses are necessary for strains that test positive.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

1-(1-naphthylmethyl)-piperazine Inhibition assay successfully rules out efflux pump overexpression in Acinetobacter baumannii

  • 期刊论文

  • 发表日期：

    2025年7月18日

查看全文
  • Victor Zosim,
  • Catherine Mullie,
  • François Peltier,
  • Anaïs Potron,
  • Morgane Choquet

摘要

Background

Antimicrobial resistance (AMR) in Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp. (ESKAPE pathogens), notably in carbapenem-resistant Acinetobacter baumannii, is a pressing global health concern, contributing to significant AMR-associated mortality. Efflux pump overexpression plays a crucial role in the multidrug resistance (MDR) of A. baumannii, but the identification of efflux-overexpressing strains remains challenging.

Methods and results

We evaluated the performance of an efflux pump inhibition assay in comparison with RT-qPCR, to assess efflux pump overexpression in a collection of clinical A. baumannii strains. Sixty MDR strains and a wild one were analyzed. The inhibition assay was positive for 34 and negative for 27 strains, respectively. Results were in agreement with RT-qPCR in 67.2% of the tested strains (39/58). Cohen’s kappa showed a fair agreement between inhibition assay and RT-qPCR (Cohen’s kappa = 0.37). Inhibition by 1-(1-NaphthylMethyl)-Piperazine (NMP), but not by Phenylalanine-Arginine-β-Naphthylamide (PaβN), was in moderate agreement with RT-qPCR (Cohen’s kappa = 0.41). Furthermore, gpi alleles were associated with efflux pump overexpression (p = 0.03), suggesting potential links between genetic diversity and efflux pump overexpression. RT-qPCR showed a significant efflux pump overexpression for 4 (16.7%) out of 24 inhibition assay negative strains.

Conclusions

Our findings support the ability to reliably rule out efflux pump overexpression in A. baumannii strains displaying a negative result with an inhibition test relying on NMP. However, confirmatory analyses are necessary for strains that test positive.